BELLUS Health Inc BLU:NASDAQ

RT Quote | NASDAQ | USD
Last | 05/20/22 EDT
8.25quote price arrow down-0.24 (-2.83%)
Volume
549,126
52 week range
2.60 - 9.84
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close8.25
  • 52 Week High9.84
  • 52 Week High Date12/13/21
  • 52 Week Low2.60
  • 52 Week Low Date07/19/21

Key Stats

  • Market Cap880.69M
  • Shares Out106.75M
  • 10 Day Average Volume0.89M
  • Dividend-
  • Dividend Yield-
  • Beta0.17
  • YTD % Change2.48

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close8.25
  • 52 Week High9.84
  • 52 Week High Date12/13/21
  • 52 Week Low2.60
  • 52 Week Low Date07/19/21
  • Market Cap880.69M
  • Shares Out106.75M
  • 10 Day Average Volume0.89M
  • Dividend-
  • Dividend Yield-
  • Beta0.17
  • YTD % Change2.48

RATIOS/PROFITABILITY

  • EPS (TTM)-0.83
  • P/E (TTM)-9.89
  • Fwd P/E (NTM)-9.79
  • EBITDA (TTM)-72.45M
  • ROE (TTM)-33.82%
  • Revenue (TTM)20,000.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-436,406.30%
  • Debt To Equity (MRQ)0.30%

EVENTS

  • Earnings Date08/09/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On BELLUS Health Inc

There is no recent news for this security.

Profile

MORE
BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with...
Francesco Bellini Ph.D.
Chairman of the Board
Roberto Bellini
President, Chief Executive Officer, Director
Ramzi Benamar
Chief Financial Officer
Francois Desjardins CPA
Vice President - Finance
Address
275 Armand-Frappier Blvd
Laval, QC
H7V 4A7
Canada